# US 2021/0267954 A1 · Granules containing diamine derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267954 A1
- Document ID: US20210267954A1
- Status: Published application
- Kind: A1
- Application number: 17/255,721
- Filed: 2019-06-26
- Published: 2021-09-02
- Earliest claimed: 2018-06-27
- Assignees: Daiichi Sankyo Company, Limited
- Applicants: Daiichi Sankyo Company, Limited
- Inventors: Wolfgang SCHMID; Maren KUHLI; Christoph SCHUH
- Web page: https://patentgrep.com/patent/US20210267954A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.

## Claims

### Claim 1

A granular preparation comprising
first granules containing
(A) edoxaban or a pharmacologically acceptable salt thereof,
(B) a sugar alcohol, and
(C) a water-swelling additive, and
second granules containing
(D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and
(E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.

### Claim 2 (depends on 1)

The granular preparation according to claim 1, wherein the ratio (R2/R1) of the median size of the second granules (R2) to the median size of the first granules (R1) is 0.75 to 1.75.

### Claim 3 (depends on 1)

The granular preparation according to claim 1, wherein the median size (X50) of the first granules is 130 μm to 240 μm, and the median size (X50) of the second granules is 170 μm to 240 μm.

### Claim 4 (depends on 1)

The granular preparation according to claim 1, wherein the granular preparation comprises 0.3 to 10% by weight of edoxaban or a pharmacologically acceptable salt thereof (A) with respect to the total weight of the preparation.

### Claim 5 (depends on 1)

The granular preparation according to claim 1, wherein edoxaban or a pharmacologically acceptable salt thereof (A) is edoxaban tosylate monohydrate.

### Claim 6 (depends on 1)

The granular preparation according to claim 1, wherein the sugar alcohol (B) is D-mannitol, xylitol, or erythritol.

### Claim 7 (depends on 6)

The granular preparation according to claim 6, wherein the sugar alcohol (B) is D-mannitol.

### Claim 8 (depends on 1)

The granular preparation according to claim 1, wherein the granular preparation comprises 3 to 15% by weight of the sugar alcohol (B) with respect to the total weight of the preparation.

### Claim 9 (depends on 1)

The granular preparation according to claim 1, wherein the water-swelling additive (C) is pregelatinized starch and/or crystalline cellulose.

### Claim 10 (depends on 9)

The granular preparation according to claim 9, wherein the water-swelling additive (C) is pregelatinized starch.

### Claim 11 (depends on 1)

The granular preparation according to claim 1, wherein the granular preparation comprises 1 to 10% by weight of the water-swelling additive (C) with respect to the total weight of the preparation.

### Claim 12 (depends on 1)

The granular preparation according to claim 1, further comprising a disintegrant.

### Claim 13 (depends on 12)

The granular preparation according to claim 12, wherein the disintegrant is contained in the first granules.

### Claim 14 (depends on 12)

The granular preparation according to claim 12, wherein the disintegrant is crospovidone and/or sodium carboxymethyl starch.

### Claim 15 (depends on 14)

The granular preparation according to claim 14, wherein the disintegrant is crospovidone.

### Claim 16 (depends on 1)

The granular preparation according to claim 1, further comprising a binder.

### Claim 17 (depends on 16)

The granular preparation according to claim 16, wherein the binder is contained in the first granules.

### Claim 18 (depends on 16)

The granular preparation according to claim 16, wherein the binder is hydroxypropylcellulose.

### Claim 19 (depends on 1)

The granular preparation according to claim 1, wherein the granular preparation is granules for an oral suspension or a dry syrup.

### Claim 20 (depends on 19)

The granular preparation according to claim 19, wherein the granular preparation is granules for an oral suspension.

### Claim 21 (depends on 19)

The granular preparation according to claim 19, wherein the granular preparation is a dry syrup.

### Claim 22 (depends on 1)

The granular preparation according to claim 1, wherein the granular preparation is used as an aqueous solution or an aqueous suspension.

### Claim 23 (depends on 1)

An aqueous solution or an aqueous suspension of the granular preparation according to claim 1.

### Claim 24

(canceled)

### Claim 25

A method for producing a granular preparation, comprising
i. a step of obtaining first granules by wet-granulating
(A) edoxaban or a pharmacologically acceptable salt thereof,
(B) D-mannitol,
(C) pregelatinized starch,
(D) crospovidone, and
(E) hydroxypropylcellulose
using water or an aqueous solution of the hydroxypropylcellulose (E),
ii. a step of obtaining second granules by wet-granulating
(F) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and
(G) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation
using water or an aqueous solution of the carmellose sodium (F), and
iii. a step of mixing the first granules and the second granules obtained.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the wet granulation is fluidized-bed granulation.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the ratio (R2/R1) of the median size of the second granules (R2) to the median size of the first granules (R1) is 0.75 to 1.75.

### Claim 28 (depends on 25)

The method according to claim 25, wherein the median size (X50) of the first granules is 130 μm to 240 μm, and the median size (X50) of the second granules is 170 μm to 240 μm.

### Claim 29 (depends on 25)

The method according to claim 25, wherein the granular preparation is granules for an oral suspension or a dry syrup.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the granular preparation is granules for an oral suspension.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the granular preparation is a dry syrup.
